Many Locations, Japan
NCT Number: NCT01401114
Wellnara Post-marketing Surveillance in Japan
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Wellnara for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Wellnara in clinical practice. A total 400 patients will be recruited and followed 3 years since starting Wellnara administration.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
Female
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients who received Wellnara for postmenopausal osteoporosis
Exclusion criteria
- Patients who are contraindicated based on the product label
Treatment and study plan
E2/LNG oral (Wellnara, BAY86-5029)
DrugPatients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
Primary outcomes
-
Incidence of adverse drug reactions and serious adverse events in subject who received Wellnara
Time frame: After Wellnara administration, up to 3 years
Secondary outcomes
-
Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease) and dose of Wellnara
Time frame: At baseline and after Wellnara administration, up to 3 years
-
Effectiveness evaluation assessment by the three rank scales: improvement, not changed, and worse
Time frame: At baseline and after Wellnara treatment, up to 3 years
Sponsors and collaborators
Lead sponsor
Bayer
Industry
Registry information
Official study title
Drug Use Investigation of Wellnara Tablet
Acronym: WELLNARA
Important dates
- Study start
- 2009
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Jul 25, 2011
- Registry last updated
- Sep 28, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
NCT05493761
Bone Diseases, Bone Diseases, Metabolic
Thessaloniki, Greece
View Trial DetailsTherapeutic Prospects of HMG-CoA Reductase Inhibitors, Atorvastatin and Rosuvastatin, in Osteoporotic Patients
NCT07717788
Bone Diseases, Bone Diseases, Metabolic
Najaf, Iraq
View Trial DetailsThe Effect of the Probiotic Strains on Bone Mineral Density in Postmenopausal Women
NCT06375668
Bone Density, Low, Bone Diseases
Bytom, Poland
View Trial DetailsMulticenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND
NCT05395091
Bone Diseases, Bone Diseases, Metabolic
Plovdiv, Bulgaria
View Trial Details